We design, found and capitalize AI-native healthcare ventures from first principles. Shared infrastructure replaces the $3–5M of validation burn that kills most seed-stage startups.
A venture studio absorbs founder, technology and validation risk inside the studio — before external capital is committed.
Thesis-driven concepting with clinical KOLs. 20+ concepts per quarter — only 2–3 advance through our scoring framework.
60–90 day sprints: clinical validation, customer discovery, technical feasibility. 3–5 signed LOIs trigger formation.
We pair clinicians with technical co-founders from our EIR pipeline — manufacturing the bilingual founders this space demands.
$500K–$1M formation check. Studio retains 30–45% equity. Shared infrastructure means capital goes to scale, not setup.
HIPAA-native data platform, clinical partnerships, regulatory counsel, MLOps — every venture launches with 12+ months of infrastructure.
At product-market fit, the venture transitions to board oversight. Studio exercises pro-rata through Series A. Target 40–50% graduation.
Six concentrated verticals. No more than 30% of capital in any single pillar.
Ambient documentation, clinical reasoning copilots, specialty diagnostic assistants, physician workflow.
Protein engineering, target identification, ADMET prediction, wet-lab-in-the-loop platforms.
Radiology, pathology, multi-modal diagnostics, point-of-care imaging, ambient diagnostic capture.
Revenue cycle, prior authorization, claims adjudication, staffing optimization, patient access.
Engagement, adherence, chronic-disease coaching, mental health, remote monitoring, navigation.
HIPAA-native data pipelines, model governance, clinical evaluation, synthetic data, compliance tooling.
The bilingual founder is rare. We manufacture them. The first-round burn is brutal. We absorb it.
Operator-investor bridging AI and healthcare. Emilio brings deep experience across venture building, pharmaceutical investment, healthcare technology and capital markets — the combination required to build category-defining companies at the intersection of artificial intelligence and clinical practice.
Reduced management fee for the first $20M of commitments. Minimum ticket $250K. Available to accredited investors and qualified purchasers.